House committee approves bill limiting some medical transition treatments for minors after contentious debate

The House Committee on Health and Human Services and Elderly Affairs voted to advance HB 377 as amended, a bill that would restrict access to certain puberty‑blocking and cross‑sex hormone treatments for minors. The committee adopted an amendment that provides a transition period for minors already on such treatments, but rejected an amendment that would have exempted more existing cases.

Committee members debated the bill for more than an hour, with supporters saying it protects children from long‑term medical decisions they may later regret and opponents saying it unduly intrudes on parents and the practice of medicine. Representative Mazur, sponsor of the bill, said the legislation is aimed at protecting minors and noted the committee had considered multiple amendments to address practical concerns. Representative Weber, who proposed an amendment to grandfather minors already on a course of medical treatment, argued that stopping treatment would be “an unreasonable intrusion into the practice of medicine and an unreasonable intrusion into the right of parents.” Weber urged a positive vote on his amendment but that proposal failed on a roll call vote.

A second amendment, introduced by Representative Mesa, allowed providers to continue transition‑related hormone treatments that had already begun and to complete a tapering period after the bill’s effective date; that amendment passed on a 15–3 vote. After procedural votes to reconsider an earlier amendment, the committee ultimately voted 10–8 to advance HB 377 as amended.

Opponents repeatedly framed the issue as one of parental rights and medical judgment. Representative Woods said “parents’ rights are supreme” and urged consistency with other bills addressing parental decision‑making. Representative McGrath, a pharmacist, stressed the need for caution about powerful drugs, citing past medical practices later revised for safety reasons. Supporters pointed to international and recent reviews and to testimony from constituents. Representative Weber and others argued that restricting these treatments is discriminatory toward a distinct class of minors and an unwarranted intrusion into medical practice.

The committee record shows several procedural steps: an initial amendment offered by Representative Weber was defeated 7–11; Mesa’s amendment providing a post‑enactment tapering period passed 15–3; a motion to reconsider a previously adopted amendment passed unanimously, but a re‑adoption vote of that reconsidered amendment later failed 0–18; the final committee motion to advance HB 377 as amended passed 10–8. The committee chair said a minority report would be submitted.

The bill now moves to the next stage of legislative consideration. Because the committee adopted an amendment that allows a tapering period for existing patients, providers and families would have a limited window to adjust care if the statute takes effect.